By Eric Johnsson, BIA Policy & Public Affairs Executive.
The party conference season is over for another year and while not everything went according to plan, the BIA’s events were successful. With parliament back in full swing and Brexit negotiations back in not-quite-so-full-swing, it has been a busy two weeks in politics since the conference season ended but here we look back at the BIA’s party conference activity.
Last Thursday we held one of the most stimulating and vibrant events of the BIA calendar – the UK Bioscience Forum. Taking place at the Queen Elizabeth II Centre in Westminster, the UKBSF brought together almost 300 people from across the sector for a jam-packed day of networking, presentations, and panel discussions.
In this exclusive interview, filmed at ISCT 2017, RegMedNet spoke to Keith Thompson, CEO, Cell and Gene Therapy Catapult. Keith discussed the advances that the Catapult have supported in their first 5 years, as well as what he hopes to achieve in the next 5.
Every now and then, the term “Northern Powerhouse” is spotted in the headlines, and more often than not, the ensuing article is about calls for infrastructure investments. But there is exciting science across the UK, including in the North of England – so what does the Northern Powerhouse mean for the life sciences?
Locate Therapeutics' IntraStem Intracellular Delivery System offers the possibility of increasing MSC transfection rates by up to 200%
Combined with the TAOS Matrix, IntraStem can deliver antibodies, magnetic nanoparticles (MNPs) and nucleic acids (plasmid (p)DNA, mRNA and siRNA) into cells at much higher levels than the current alternatives for reprogramming, as well as improving gene editing, using for example, the CRISPR-cas9 approach
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Dr Cliff Holloway as Chief Executive Officer of Scancell, starting 10 January 2018. Cliff will seek to drive progress of Scancell’s immunotherapy platforms ImmunoBody® and Moditope® and oversee their commercialisation. Cliff succeeds Richard Goodfellow who will remain on the Company’s Board of Directors.
The development of managers in the biopharmaceutical and cell and gene therapy industries is an important part of the training landscape to deliver senior leaders of the future. A MAC (manufacturing advisory committee) initiative to support this development, kicking off with a group of 11 people from UK BIA member companies in January 2017, is now almost half way through. Members visit each participating company to build a network, gain an insight into the work of other companies in the sector by seeing them in action, share best practice and develop relationships to encourage possible future collaborations. The staff on the exchange benefit from a broader view and an ability to challenge their current business with new ideas and approaches, which some have taken back to their respective s
In an overlooked part of her speech to the Conservative Part Conference the Prime Minister said, “we are a nation of dreamers, with the capacity to deliver on those dreams too,” and there is no better example of that than the development of Nobel winning cryo-electron microscopy.